- ►annals.org [PDF] HR Buller, BL Davidson, H Decousus, A … - Annals of internal medicine, 2004 - Am Coll Physicians Background: The current standard initial therapies for deep venous thrombosis
are low-molecular-weight heparin and unfrac- tionated heparin. In a dose-ranging
study of patients with symp- tomatic deep venous thrombosis, fondaparinux ... Cited by 237 - Related articles - BL Direct - All 13 versions
HR Büller, BL Davidson, H Decousus, A … - The New England journal of medicine, 2003 - ncbi.nlm.nih.gov 1: N Engl J Med. 2003 Oct 30;349(18):1695-702. Erratum in: N Engl J Med. 2004 Jan
22;350(4):423. Comment in: ACP J Club. 2004 May-Jun;140(3):68. N Engl J Med. ... Cited by 243 - Related articles - BL Direct - All 2 versions
- ►pubget.com [PDF] AGG Turpie, KA Bauer, BI Eriksson, MR … - Archives of Internal Medicine, 2002 - archinte.highwire.org Methods A meta-analysis of 4 multicenter, randomized, double-blind trials in
patients undergoing elective hip replacement, elective major knee surgery, and
surgery for hip fracture (N = 7344) was performed to determine whether a ... Cited by 427 - Related articles - BL Direct - All 5 versions
- ►thrombosedialog.de [PDF] S Schulman, K Wahlander, T Lundstrom, SB … - The New England journal of medicine, 2003 - nejm.highwire.org Results Data from 612 patients in the ximelagatran group and 611 in the placebo
group were analyzed. The occurrence of the primary end point, symptomatic
recurrent venous thromboembolism, was confirmed in 12 patients assigned to ... Cited by 348 - Related articles - BL Direct - All 35 versions
CJ Van Dongen, AG van Den Belt, MH Prins, … - Cochrane Database Syst Rev, 2004 - vitualis.wordpress.com This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
Collaboration and published in The Cochrane Library 2006, Issue 2 ... Fixed
dose subcutaneous low molecular weight heparins versus adjusted dose ... Cited by 274 - Related articles - View as HTML - All 8 versions
SS Shapiro - New England Journal of Medicine - content.nejm.org Methods We conducted a randomized, open-label trial involving 2213 patients with
acute symptomatic pulmonary embolism to compare the efficacy and safety of the
synthetic antithrombotic agent fondaparinux with those of unfractionated ... Related articles - All 2 versions
JN Fiessinger, MV Huisman, BL Davidson, H … - Jama, 2005 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Ximelagatran, an ... Cited by 101 - Related articles - All 8 versions
- ►annals.org [PDF] G Merli, TE Spiro, CG Olsson, U Abildgaard, … - Annals of internal medicine, 2001 - Am Coll Physicians Background: Low-molecular-weight heparins administered sub- cutaneously once or
twice daily have been reported to be as safe and efficacious as intravenous
unfractionated heparin in the treat- ment of acute venous thromboembolic ... Cited by 222 - Related articles - BL Direct - All 11 versions
- ►hematologylibrary.org P Savi, BH Chong, A Greinacher, Y Gruel, JG … - Blood, 2005 - bloodjournal.hematologylibrary.org Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy
caused by antibodies against a complex of platelet factor 4 and heparin.
Fondaparinux (Arixtra) is a new synthetic selective factor Xa inhibitor. We ... Cited by 110 - Related articles - All 5 versions
HR Buller, AT Cohen, B Davidson, H Decousus, … - The New England journal of medicine, 2007 - citation.nstl.gov.cn BACKGROUND: Venous thromboembolism is treated with unfractionated heparin or
low-molecular-weight heparin, followed by a vitamin K antagonist. We
investigated the potential use of idraparinux, a long-acting inhibitor of ... Cited by 45 - Related articles - Cached - All 3 versions
